美托洛尔与卡维地洛对高血压患者的血压控制效果及对糖脂代谢的影响比较
|
摘要
目的比较分析美托洛尔与卡维地洛对高血压患者的血压控制效果及糖脂代谢的影响。方法 162例高血压患者,采取分层随机法分为美托洛尔组与卡维地洛组,每组81例。美托洛尔组采取美托洛尔治疗,卡维地洛组采取卡维地洛治疗。比较两组患者的血压控制效果及糖脂代谢水平。结果两组患者治疗后舒张压、收缩压比较差异均无统计学意义(P>0.05)。卡维地洛组患者空腹血糖、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平分别为(5.65±0.34)、(1.78±0.21)、(5.79±1.00)、(3.49±0.59)mmol/L,均低于美托洛尔组的(6.09±0.41)、(2.21±0.40)、(6.20±1.17)、(3.80±0.68)mmol/L,高密度脂蛋白胆固醇(HDL-C)水平(1.51±0.20)mmol/L高于美托洛尔组的(1.25±0.14)mmol/L,差异均具有统计学意义(P<0.05)。结论卡维地洛在降压的同时对患者糖脂代谢有着正面影响,较美托洛尔更加全面,总体疗效也更有优势,具有较高的临床价值。
Objective To compare and analyze the effect of metoprolol and carvedilol on blood pressure control and glycolipid metabolism in hypertension patients. Methods A total of 162 hypertension patients were divided by stratified random method into metoprolol group and carvedilol group, with 81 cases in each group. Metoprolol group was treated with metoprolol, and carvedilol group was treated with carvedilol. Comparison were made on blood pressure control effect and glycolipid metabolism level between two groups. Results Both groups had no statistically significant difference in diastolic blood pressure and systolic blood pressure after treatment(P>0.05). Carvedilol group had lower fasting blood glucose, triglyceride(TG), total cholesterol(TC), low density lipoprotein cholesterol(LDL-C) respectively as(5.65±0.34),(1.78±0.21),(5.79±1.00) and(3.49±0.59) mmol/L than(6.09±0.41),(2.21±0.40),(6.20±1.17) and(3.80±0.68) mmol/L in metoprolol group, and higher high density lipoprotein cholesterol(HDL-C) as(1.51±0.20) mmol/L than(1.25±0.14) mmol/L in metoprolol group. Their difference was statistically significant(P<0.05). Conclusion Carvedilol has a positive effect on glycolipid metabolism while lowering blood pressure in patients with hypertension, and it is more comprehensive than metoprolol, and its overall efficacy is also more advantageous. It contains high clinical value.
Objective To compare and analyze the effect of metoprolol and carvedilol on blood pressure control and glycolipid metabolism in hypertension patients. Methods A total of 162 hypertension patients were divided by stratified random method into metoprolol group and carvedilol group, with 81 cases in each group. Metoprolol group was treated with metoprolol, and carvedilol group was treated with carvedilol. Comparison were made on blood pressure control effect and glycolipid metabolism level between two groups. Results Both groups had no statistically significant difference in diastolic blood pressure and systolic blood pressure after treatment(P>0.05). Carvedilol group had lower fasting blood glucose, triglyceride(TG), total cholesterol(TC), low density lipoprotein cholesterol(LDL-C) respectively as(5.65±0.34),(1.78±0.21),(5.79±1.00) and(3.49±0.59) mmol/L than(6.09±0.41),(2.21±0.40),(6.20±1.17) and(3.80±0.68) mmol/L in metoprolol group, and higher high density lipoprotein cholesterol(HDL-C) as(1.51±0.20) mmol/L than(1.25±0.14) mmol/L in metoprolol group. Their difference was statistically significant(P<0.05). Conclusion Carvedilol has a positive effect on glycolipid metabolism while lowering blood pressure in patients with hypertension, and it is more comprehensive than metoprolol, and its overall efficacy is also more advantageous. It contains high clinical value.
引文
[1]刘青青,陈瑶,肖雨婷.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.中国全科医学,2013,16(9):1035-1037.
[2]Patel DP,Sharma P,Sanyal M,et al.UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4'-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers.Biomedical Chromatography Bmc,2013,27(8):974.
[3]刘立立,张伶俐,曾力楠,等.卡维地洛联合螺内酯治疗难治性高血压的系统评价.医药导报,2015,34(s1):141-144.
[4]陈鹏,王学之.卡维地洛和美托洛尔治疗高血压效果及对糖脂代谢的影响.现代中西医结合杂志,2014,23(7):717-719.
[5]赵博雅.卡维地洛与倍他乐克治疗老年应激性高血压的疗效比较.中国老年学杂志,2013,33(10):2253-2254.
[6]童赣冬.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.中国医药指南,2013(23):596.
[7]陈宁,王景春,关慧.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.中国伤残医学,2014(23):103-104.
[8]沈如胜.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.医药前沿,2014,30(29):130-131.
[9]齐新颜.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的随机对照研究.临床医学,2014,34(10):25-26.
[10]马丹.比较卡维地洛与美托洛尔治疗高血压临床效果及其对糖脂代谢的影响.临床合理用药杂志,2015(2):68-69.
[2]Patel DP,Sharma P,Sanyal M,et al.UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4'-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers.Biomedical Chromatography Bmc,2013,27(8):974.
[3]刘立立,张伶俐,曾力楠,等.卡维地洛联合螺内酯治疗难治性高血压的系统评价.医药导报,2015,34(s1):141-144.
[4]陈鹏,王学之.卡维地洛和美托洛尔治疗高血压效果及对糖脂代谢的影响.现代中西医结合杂志,2014,23(7):717-719.
[5]赵博雅.卡维地洛与倍他乐克治疗老年应激性高血压的疗效比较.中国老年学杂志,2013,33(10):2253-2254.
[6]童赣冬.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.中国医药指南,2013(23):596.
[7]陈宁,王景春,关慧.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.中国伤残医学,2014(23):103-104.
[8]沈如胜.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的对比分析.医药前沿,2014,30(29):130-131.
[9]齐新颜.卡维地洛和美托洛尔治疗高血压的疗效及其对糖脂代谢影响的随机对照研究.临床医学,2014,34(10):25-26.
[10]马丹.比较卡维地洛与美托洛尔治疗高血压临床效果及其对糖脂代谢的影响.临床合理用药杂志,2015(2):68-69.